|
Hematologic Malignancies FY17 |
01/27/2017 - 9:00am to 10:00am EST |
|
Hematologic Malignancies FY17 "Kidney Diseases Associated with Plasma Cell Dyscrasia” |
02/03/2017 - 9:00am to 10:00am EST |
|
Hematologic Malignancies FY17 Controversies in Advanced Hodgkin Lymphoma: BEACOPP, Interim PET and (of course) RT |
02/10/2017 - 9:00am to 10:00am EST |
|
Hematologic Malignancies FY17 Hepatosplenic T-cell Lymphoma |
02/17/2017 - 9:00am to 10:00am EST |
|
Hematologic Malignancies FY17 “Outcomes of High Dose BCNU/HDM Preparative Regimen in Newly Diagnosed Multiple Myeloma” |
02/24/2017 - 9:00am to 10:00am EST |
|
Hematologic Malignancies FY17 Extracorporeal Photopheresis (ECP) for the treatment of GVHD |
03/03/2017 - 9:00am to 10:00am EST |
|
Hematologic Malignancies FY17 B-Cell Fate and Function after Stem Cell Transplantation |
03/10/2017 - 9:00am to 10:00am EST |
|
Hematologic Malignancies FY17 Mock Panel: Should Mylotarg Recieve (Re) Approval for AML? |
03/17/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 New horizons in treating relapsed/refractory ALL |
03/24/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancies FY17 An App a Day to Keep the Doctor Away |
03/31/2017 - 9:00am to 10:00am EDT |
Facebook
X
LinkedIn
Forward